Are Sirtex’s best days behind it?

Sirtex shareholders have been on a rollercoaster ride. But are its latest clinical trial results really as bad as they look?

Traditionally, the biotech space has been the wild west of the ASX; reserved for gun-slinging investors who feel small-cap mining doesn’t offer enough risk and excitement. Sirtex Medical hasn’t let them down.

After almost doubling to a giddy high of $40 in the space of six months, Sirtex’s share price collapsed 60% on March 17 after the company released the results of a seven-year clinical trial.


SMS Code Sent…

Hi {{ user.FirstName }}

Looks like you've already taken a free trial

Please enter your payment details

We have sent you a code via SMS to {{user.DayPhone}}

please enter this code below to activate your membership

If you didn't receive SMS code please

Looks you are already a member. Please enter your password to proceed

Please untick this box when using a public or shared device

Verify your mobile number

Please sign up for full access

Updating information

Please wait ...

  • Mastercard
  • Visa

Related Articles